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Background: This multicentre cohort study sought to define a robust pathological indicator of clinically
meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma.
Methods: A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine
the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients
undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were
reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour
Regression Grade (TRG) and lymph node downstaging.
Results: TRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant
chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG
assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and
TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1–2;
median overall survival (OS) not reached) and non-responders (TRG 3–5; median OS 2⋅22 (95 per cent
c.i. 1⋅94 to 2⋅51) years; P<0⋅001); the hazard ratio was 2⋅46 (95 per cent c.i. 1⋅22 to 4⋅95; P= 0⋅012).
Among local non-responders, the presence of lymph node downstaging was associated with significantly
improved OS compared with that of patients without lymph node downstaging (median OS not reached
versus 1⋅92 (1⋅68 to 2⋅16) years; P<0⋅001).
Conclusion: A clinically meaningful local response to neoadjuvant chemotherapy was restricted to the
small minority of patients (14⋅8 per cent) with TRG 1–2. Among local non-responders, a subset of
patients (21⋅3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging
and their survival mirrored that of local responders.
∗Members of the OCCAMS consortium are co-authors of this article and can be found under the heading Collaborators.
Paper accepted 30 May 2017
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Introduction
Neoadjuvant chemotherapy (NAC) followed by surgery,
along with perioperative chemotherapy and neoadju-
vant chemoradiotherapy, is a standard of care in the
management of patients with locally advanced adeno-
carcinoma of the oesophagus and oesophagogastric junc-
tion (OGJ) in the UK1. The potential benefits of NAC
include: downstaging of the primary tumour2 and lymph
nodes3, increased tumour resectability4, elimination of
micrometastases5 and improved survival6. Early assess-
ment of response to NAC may provide information to
tailor multimodal therapy7.
Both NAC and surgery are associated with considerable
morbidity and mortality8, and evidence remains incon-
sistent for the survival benefit for patients who undergo
NAC4,8,9. The most recent meta-analysis6 to compare
NAC versus surgery alone in 2062 patients suggested a
5⋅1 per cent absolute survival advantage at 2 years for
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patients treated with NAC for adenocarcinoma. This is
because only a small minority of patients have a signifi-
cant pathological response to neoadjuvant therapy and it is
these patients who gain a significant survival benefit from
NAC10,13.
There are numerous methods for assessing pathological
response to neoadjuvant therapy, but no universal measure
is used consistently10,14–18. The majority were developed
for patients who underwent neoadjuvant chemoradiother-
apy and did not differentiate patients based on histology.
Few have been validated in patients with oesophageal
adenocarcinoma undergoing NAC2,19–22. Use of the
Tumour Regression Grade (TRG) described by Mandard
and colleagues23 is suggested by UK guidelines, although
this has not gained universal acceptance, and the guide-
lines give no detail regarding how TRG should be used
to guide therapy decisions1,17. This system is based on
the amount of residual tumour and degree of fibrosis at
the primary tumour site, which is graded on a five-point
scale23. Reports from single-centre cohorts20,24 and from
small subsets of larger multicentre trials25 have identified
a significant survival advantage with Mandard TRG 1–2
or TRG 1–3, further confusing clinical decision-making.
A number of clinically important questions could be
addressed by a robust and universally accepted measure of
response to neoadjuvant treatment, including the devel-
opment of biomarkers to accurately predict an individ-
ual patient’s tumour response to preoperative therapy;
this would lead to non-responders proceeding directly to
surgery or being considered for alternative neoadjuvant
regimens, and the identification of patients who are likely
to benefit from adjuvant therapy in new stratified trials.
This multicentre cohort study evaluated the current sta-
tus of neoadjuvant response assessment in multidisciplinary
team decision-making via a questionnaire, and aimed to
define and validate the pathological assessment of response
to NAC in treated oesophagogastric adenocarcinoma. The
aim was to provide a consistent, simple, robust and univer-
sally acceptable method to assess response to neoadjuvant
therapy to allow wider application for both clinical use and
biomarker discovery.
Methods
Questionnaire
A questionnaire was distributed to 11 upper gastrointesti-
nal cancer centres, all part of the Oesophageal Cancer
Clinical and Molecular Stratification (OCCAMS) consor-
tium, to assess the current use of neoadjuvant response
assessment in clinical practice (Appendix S1, supporting
information). The OCCAMS consortium is a UK-wide
multicentre consortium to facilitate clinical and molecular
stratification of oesophagogastric cancer, with ethical
approval for biological sample collection and analysis in
conjunction with detailed clinical annotation (Research
Ethics Committee number 10/H0305/1).
Patients
The records of consecutive patients undergoing oesopha-
gogastric resection (tumours of the oesophagus and OGJ
only were included) treated at seven centres (University
Hospital Southampton NHS Foundation Trust, Belfast
Health and Social Care Trust, University Hospitals Birm-
ingham NHS Foundation Trust, University Hospital
Cambridge NHS Foundation Trust, Royal Infirmary of
Edinburgh, Portsmouth NHS Trust, Nottingham Uni-
versity Hospitals NHS Trust) between January 2000 and
December 2013 were reviewed as part of the OCCAMS
consortium. All patients were discussed at a special-
ist multidisciplinary team meeting. Standard staging
investigations included high-resolution CT, endoscopic
ultrasonography, and latterly integrated fluorodeoxy-
glucose PET–CT and staging laparoscopy, where indi-
cated. Patients deemed suitable for potential surgical
resection with tumours staged as cT2 Nx M0 or cTx N+
M0 were considered for NAC based on local practice and
national guidelines1.
NAC mainly consisted of cisplatin and 5-fluorouracil
(5-FU) (two cycles of cisplatin 80 mg/m2 intravenously
on day 1 and intravenous infusion of 5-FU 1000 mg/m2
over 96 h) or platinum-based triplet therapy. The latter
comprised three 21-day cycles of anthracycline, plat-
inum and fluoropyrimidine: ECF (epirubicin 50 mg/m2,
cisplatin 60 mg/m2, both intravenously on day 1 and
protracted venous infusion of 5-FU 200 mg/m2 per day)
or ECX (epirubicin 50 mg/m2, cisplatin 60 mg/m2, both
intravenously on day 1 and capecitabine 625 mg/m2 orally
twice daily for 21 days) or EOX (epirubicin 50 mg/m2
intravenous bolus and oxaliplatin 130 mg/m2 intravenous
infusion over 2 h on day 1, capecitabine 625 mg/m2 orally
twice daily for 21 days).
CT or PET–CT was repeated before surgery to assess
the response to chemotherapy and disease operability.
Data recorded included demographics, tumour charac-
teristics, resection type and histopathological analysis of
the surgical specimen. The TNM classification (7th edi-
tion) was used to report tumour stage after analysis of
pathology reports26. Pathological tumour clearance (R sta-
tus) was determined according to the Royal College of
Pathologists’ guidance.
Overall survival (OS) was defined as time from operation
to date of death from any cause or date of last review.
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1816–1828
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n = 1441
n = 1402
n = 1397
n = 1392
Excluded: non-oesophageal/GOJ cancers n = 59
Excluded: surgery only n = 39
Excluded: nonsensical dates n = 5
Excluded: no survival data n = 5
Analysis of nodal status n = 981Analysis of TRG and nodal
status n = 885
Excluded: TGR and/or nodal
 status not recorded n = 507Excluded: TRG not recorded n = 99
Analysis of TRG n = 1293
Nottingham
n = 501
Portsmouth
n = 93
Southampton
n = 274
Excluded: cN and/or pN not
 recorded n = 411
Fig. 1 Flow diagram showing numbers of patients contributed by participating centres. GOJ, gastro-oesophageal junction; TRG,
Tumour Regression Grade
Factors analysed
Pathological response to chemotherapy was assessed using
the TRG system, with regression based on the degree of
fibrosis and residual cancer cells (TRG 1–5)23,27.TRG was
scored by specialist gastrointestinal pathologists blinded
to the clinical data at the treating cancer centre. Some 10
per cent of cases were validated externally by an indepen-
dent pathologist as part of the OCCAMS/International
Cancer Genome Consortium project28,29 with a κ value
exceeding 0⋅8.
All dissected lymph nodes were stained with haema-
toxylin and eosin, and analysed microscopically for
metastatic disease. Lymph node downstaging was defined
as any regional lymph node that was positive on clinical
evaluation (cN+) which subsequently had no evidence
of pathological regional lymph node disease (ypN0), as
described previously24.
Statistical analysis
Descriptive data are presented as median (range)
unless stated otherwise. Data were analysed using the
Kruskal–Wallis, Mann–Whitney U and Pearson’s χ2 tests,
as appropriate. Kaplan–Meier analysis, and univariable and
multivariable Cox logistic regression modelling were used
to assess the relationship between pathological response
grading systems and OS. All factors that showed statistical
significance in univariable analysis were entered to
derive the final model. Stratified analyses were per-
formed based on receipt of NAC, nodal stage and
response to chemotherapy. P< 0⋅050 was considered
statistically significant for all tests. Statistical analysis
was undertaken in SPSS® version 22 (IBM, Armonk,
New York, USA).
Results
Current clinical use of response assessment
to neoadjuvant chemotherapy
The responses from 11 UK cancer centres demonstrated
that TRG was the system most widely used to assess
response to NAC (used in 8 of 11 centres), and felt to be
useful in providing prognostic information for the patient
(8 of 11) and making decisions about the modification of
adjuvant therapy (9 of 11). There was no consensus on
how TRG was being used to influence decision-making for
individual patients in practice; the centres used different
scores to define responders, with most using TRG 1–3 (5
of 8), and there was a lack of consensus on how adjuvant
therapy should be guided by TRG. Some centres would
advocate adjuvant therapy based on whether the patient
had responded to therapy (5 of 11), whereas others would
not use response information (6 of 11) (Fig. S1, supporting
information).
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1816–1828
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Table 1 Clinical and pathological characteristics of the full cohort
No. of patients (n=1392)
Preoperative status
Age (years)* 64 (26–83)
Sex ratio (M : F) 1181 : 211
cT category cT1 10 (1⋅0)
cT2 136 (13⋅8)
cT3 798 (80⋅7)
cT4 45 (4⋅6)
Unknown 403
cN category cN0 235 (23⋅8)
cN1 634 (64⋅2)
cN2 102 (10⋅3)
cN3 16 (1⋅6)
Unknown 405
cM category cM0 998 (98⋅7)
cM1 13 (1⋅3)
Unknown 381
Tumour site Oesophagus 445 (32⋅0)
Gastro-oesophageal junction 947 (68⋅0)
Siewert 1 290 (42⋅0)
Siewert 2 272 (39⋅3)
Siewert 3 130 (18⋅8)
Siewert unknown 255
Chemotherapy regimen Cisplatin + 5-fluorouracil 281 (20⋅2)
Platinum-based triplet therapy 1037 (74⋅5)
Other/unknown 74 (5⋅3)
Pathological outcomes
ypT category ypT0 65 (4⋅7)
ypT1 135 (9⋅7)
ypT2 231 (16⋅6)
ypT3 867 (62⋅4)
ypT4 91 (6⋅6)
Unknown 3
ypN category ypN0 514 (37⋅1)
ypN1 432 (31⋅2)
ypN2 246 (17⋅7)
ypN3 194 (14⋅0)
Unknown 6
ypM category ypM0 1340 (97⋅6)
ypM1 33 (2⋅4)
Unknown 19
Tumour response TRG 1 76 (5⋅9)
TRG 2 116 (9⋅0)
TRG 3 239 (18⋅5)
TRG 4 481 (37⋅2)
TRG 5 381 (29⋅5)
Unknown 99
Nodal yield* 23 (0–75)
% positive nodes* 15⋅6 (0–100)
Patients with lymph nodes downstaged (cN1+ to ypN0) 259 of 981 (26⋅4)
Resection clearance R0 913 (66⋅6)
R1 458 (33⋅4)
Unknown 21
Vascular/lymphatic invasion Yes 447 (50⋅2)
No 443 (49⋅8)
Unknown 502
Differentiation No residual tumour 8 (0⋅9)
G1 57 (6⋅3)
G2 327 (36⋅4)
G3 429 (47⋅8)
G4 77 (8⋅6)
Unknown 494
Values in parentheses are percentages unless indicated otherwise; *values are median (range). TRG, Tumour Regression Grade.
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1816–1828
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Fig. 2 Kaplan–Meier survival analysis of patients grouped according to Tumour Regression Grade (TRG): a by individual grade and b
TRG 1–2 (responders) versus TRG 3–5 (non-responders). a,b P< 0⋅001 (log rank test)
Table 2 Overall survival rates
No. of patients Median overall survival Mean overall survival P*
TRG category <0⋅001
TRG 1 76 n.r. 7⋅46 (6⋅48, 8⋅44)
TRG 2 116 n.r. 7⋅63 (6⋅84, 8⋅43)
TRG 3 239 3⋅19 (2⋅16, 4⋅22) 4⋅90 (4⋅27, 5⋅52)
TRG 4 481 2⋅64 (2⋅15, 3⋅14) 4⋅16 (3⋅75, 4⋅58)
TRG 5 381 1⋅57 (1⋅29, 1⋅86) 3⋅39 (2⋅96, 3⋅82)
TRG group <0⋅001
TRG 1–2 192 n.r. 7⋅68 (7⋅05, 8⋅31)
TRG 3–5 1101 2⋅22 (1⋅94, 2⋅51) 4⋅06 (3⋅78, 4⋅33)
LN downstaging <0⋅001
LNs downstaged 259 n.r. 7⋅64 (7⋅08. 8⋅20)
LNs not downstaged 722 2⋅04 (1⋅78, 2⋅30) 3⋅56 (3⋅21, 3⋅99)
LN downstaging and TRG <0⋅001
TRG 1–2 142 n.r. 7⋅77 (7⋅09, 8⋅45)
TRG 3–5
LNs downstaged 158 n.r. 7⋅24 (6⋅50, 7⋅99)
LNs not downstaged 585 1⋅92 (1⋅68, 2⋅16) 3⋅29 (2⋅92, 3⋅66)
Values in parentheses are 95 per cent confidence intervals. TRG, Tumour Regression Grade; n.r., not reached; LN, lymph node. *Log rank test.
Study patients
A total of 1392 patients underwent neoadjuvant therapy
with attempted curative resection for oesophageal or OGJ
adenocarcinoma, of whom 1293 had TRG assessment.
Data were available for both clinical and pathological nodal
status (cN and pN) in 981 patients, and TRG, cN and pN
status in 885 patients (Fig. 1).
Patients were predominantly men (1181 of 1392, 84⋅8
per cent) and had a median age of 64 (range 26–83) years.
Resection clearance (R0) as defined by the Royal College
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1816–1828
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Table 3 Clinical and pathological characteristics of patients with Tumour Regression Grade available grouped as responders (TRG
1–2) and non-responders (TRG 3–5)
TRG 1–2 (n=192) TRG 3–5 (n=1101) P†
Preoperative status
Age (years)* 65 (37–79) 63 (26–83) 0⋅089‡
Sex ratio (M : F) 163 : 29 938 : 163 0⋅914
cT category cT1 3 (2⋅1) 5 (0⋅7) 0⋅101
cT2 26 (18⋅1) 97 (12⋅8)
cT3 108 (75⋅0) 625 (82⋅5)
cT4 7 (4⋅9) 31 (4⋅1)
Unknown 48 343
cN category cN0 32 (22⋅4) 170 (22⋅7) 0⋅711
cN1 96 (67⋅1) 480 (64⋅2)
cN2 14 (9⋅8) 84 (11⋅2)
cN3 1 (0⋅7) 14 (1⋅9)
Unknown 49 353
cM category cM0 145 (97⋅3) 755 (99⋅0) 0⋅109
cM1 4 (2⋅7) 8 (1⋅0)
Unknown 43 338
Tumour site Oesophagus 76 (39⋅6) 363 (33⋅0) 0⋅074
Gastro-oesophageal junction 116 (60⋅4) 738 (67⋅0)
Siewert 1 35 (40) 224 (43⋅8) 0⋅617
Siewert 2 33 (38) 198 (38⋅7)
Siewert 3 19 (22) 90 (17⋅6)
Siewert unknown 29 226
Chemotherapy regimen Cisplatin + 5-fluorouracil 14 (7⋅3) 236 (21⋅4) < 0⋅001
Platinum-based triplet therapy 160 (83⋅3) 815 (74⋅0)
Other/unknown 18 (9⋅4) 50 (4⋅5)
Pathological outcomes
ypT category ypT0 64 (33⋅7) 0 (0) <0⋅001
ypT1 49 (25⋅8) 74 (6⋅7)
ypT2 33 (17⋅4) 176 (16⋅0)
ypT3 42 (22⋅1) 770 (70⋅0)
ypT4 2 (1⋅1) 80 (7⋅3)
Unknown 2 1
ypN category ypN0 145 (75⋅9) 336 (30⋅7) < 0⋅001
ypN1 33 (17⋅3) 372 (33⋅9)
ypN2 12 (6⋅3) 213 (19⋅4)
ypN3 1 (0⋅5) 175 (16⋅0)
Unknown 1 5
ypM category ypM0 189 (99⋅0) 1058 (97⋅3) 0⋅179
ypM1 2 (1⋅0) 29 (2⋅7)
Unknown 1 14
Nodal yield* 22 (3–65) 23 (0–75) 0⋅437‡
% positive nodes* 2⋅9 (0–54⋅2) 17⋅9 (0–100) < 0⋅001‡
Patients with lymph nodes downstaged (cN1+ to ypN0) 85 of 142 (59⋅9) 158 of 742 (21⋅3) <0⋅001
Resection clearance R0 173 (92⋅5) 678 (62⋅5) < 0⋅001
R1 14 (7⋅5) 407 (37⋅5)
Unknown 5 16
Vascular/lymphatic invasion Yes 15 (11⋅6) 114 (88⋅4) 364 (54⋅9) 299 (45⋅1) <0⋅001
No 63 438
Unknown 8 (7⋅8) 0 (0) <0⋅001
Differentiation No residual tumour 20 (19⋅4) 34 (4⋅9)
G1 37 (35⋅9) 263 (37⋅7)
G2 34 (33⋅0) 332 (47⋅6)
G3 4 (3⋅9) 69 (9⋅9)
G4 89 403
Values in parentheses are percentages unless indicated otherwise; *values are median (range). TRG, Tumour Regression Grade. †Pearson’s χ2 test, except
‡Mann–Whitney U test.
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of Pathologists was achieved in 66⋅6 per cent (913 of
1371) and the median nodal yield was 23 (0–75). Patient
characteristics, and clinical and pathological outcomes are
summarized in Table 1.
Chemotherapy was the predominant neoadjuvant treat-
ment, either platinum-based triplet (1037 of 1392, 74⋅5
per cent) or cisplatin and 5-FU (281 of 1392, 20⋅2 per
cent). Chemoradiotherapy was used in three patients.
In 70⋅5 per cent of patients (912 of 1293) there were
demonstrable signs of local pathological tumour regression
(TRG 1–4); 5⋅9 per cent (76 of 1293) exhibited a com-
plete pathological response (TRG 1). Lymph node down-
staging (cN1+ to ypN0) was observed in 26⋅4 per cent
(259 of 981).
Assessment of clinically meaningful pathological
response to neoadjuvant chemotherapy
in oesophageal adenocarcinoma
Median follow-up for the 1293 patients who underwent
NAC with TRG available was 3⋅6 (95 per cent c.i. 3⋅2 to
4⋅1) years. There was a clear association between TRG and
prognosis across all groups (Fig. 2a, Table 2). A significant
difference in OS was observed for the 192 patients (14⋅8 per
cent) with TRG 1–2, defined as responders, and the 1101
(85⋅2 per cent) with TRG 3–5, defined as non-responders
(TRG 1–2: median OS not reached, mean OS 7⋅68 (95 per
cent c.i. 7⋅05 to 8⋅31) years; TRG 3–5: median OS 2⋅22
(1⋅94 to 2⋅51) years, mean OS 4⋅06 (3⋅78 to 4⋅33) years;
P< 0⋅001) (Fig. 2b). No significant difference in survival
was observed between patients with TRG 1 and those with
TRG 2 (median OS not reached in either group; mean
OS 7⋅46 (6⋅48 to 8⋅44) versus 7⋅63 (6⋅84 to 8⋅43) years;
P= 0⋅911).
Responders and non-responders had similar preop-
erative clinical features (age, sex) and clinical stage of
disease, yet responders had markedly reduced ypT cate-
gory (P< 0⋅001), ypN status (P< 0⋅001) and were more
likely to have nodal downstaging (P< 0⋅001) (Table 3).
Complete resection (R0) was achieved in 92⋅5 per cent of
responders (173 of 187) compared with 62⋅5 per cent of
non-responders (678 of 1085), and this correlated across
the five TRG groups (Table S1, supporting information).
Of patients who underwent an R1 resection, tumour
involvement was at the radial (circumferential) margin in
92⋅7 per cent, regardless of treatment centre or type of
surgery performed. There was no significant difference
in nodal yield between responders and non-responders
(P= 0⋅437).
Patients with lymph node downstaging following NAC
(259 of 981) had improved OS compared with patients
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Fig. 3 Kaplan–Meier survival analysis of patients grouped
according to lymph node (LN) downstaging. P< 0⋅001 (log rank
test)
without downstaging (lymph nodes downstaged: median
OS not reached, mean OS 7⋅64 (95 per cent c.i. 7⋅08 to
8⋅20) years; lymph nodes not downstaged: median OS 2⋅04
(1⋅78 to 2⋅30) years, mean OS 3⋅56 (3⋅21 to 3⋅99) years;
P< 0⋅001) (Fig. 3).
Univariable and multivariable analysis confirmed known
predictors of OS in oesophageal adenocarcinoma (Table 4).
Factors that retained significance for the prediction
of worse OS in multivariable analysis were: vascu-
lar/lymphatic invasion (hazard ratio (HR) 1⋅61, 95 per
cent c.i. 1⋅23 to 2⋅10; P< 0⋅001), lack of significant
response to NAC (TRG 3–5) (HR 2⋅46, 1⋅22 to 4⋅95;
P= 0⋅012), and ypN and ypM status.
Evaluation of chemotherapy regimen
Patients treated with platinum-based triplet chemotherapy
had a significantly greater response to chemotherapy in the
local tumour (TRG) and regional lymph nodes, and were
more likely to have an R0 surgical resection than those who
received cisplatin and 5-FU (Table 3; Table S2, supporting
information).
Kaplan–Meier analysis showed better OS among
patients who had platinum-based triplet chemother-
apy (Fig. S2, supporting information), but multivariable
analysis showed no difference in OS between regimens
(Table 4).
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1816–1828
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Table 4 Univariable and multivariable Cox regression analysis of patient, treatment and tumour factors associated with overall survival
for patients who received neoadjuvant chemotherapy
Univariable analysis Multivariable analysis
Hazard ratio P Hazard ratio P
Patient factors
Age 1⋅00 (0⋅99, 1⋅01) 0⋅918
Sex
F 1⋅00 (reference)
M 1⋅08 (0⋅88, 1⋅34) 0⋅458
Chemotherapy regimen
Platinum-based triplet therapy 1⋅00 (reference) 1⋅00 (reference)
Cisplatin + 5-fluorouracil 1⋅44 (1⋅22, 1⋅70) <0⋅001 1⋅07 (0⋅82, 1⋅41) 0⋅610
Tumour response
TRG category
TRG 1 1⋅00 (reference)
TRG 2 1⋅03 (0⋅54, 1⋅98) 0⋅932
TRG 3 2⋅80 (1⋅61, 4⋅89) <0⋅001
TRG 4 3⋅50 (2⋅04, 5⋅99) <0⋅001
TRG 5 4⋅81 (2⋅81, 8⋅25) <0⋅001
TRG group
TRG 1–2 1⋅00 (reference) 1⋅00 (reference)
TRG 3–5 3⋅66 (2⋅65, 5⋅06) <0⋅001 2⋅46 (1⋅22, 4⋅95) 0⋅012
Lymph nodes downstaged
Yes 1⋅00 (reference) 1⋅00 (reference)
No 3⋅99 (2⋅98, 5⋅34) <0⋅001 1⋅59 (0⋅85, 2⋅99) 0⋅149
Tumour factors
ypT category
ypT0 1⋅00 (reference) 1⋅00 (reference)
ypT1 1⋅41 (0⋅69, 2⋅87) 0⋅343 0⋅59 (0⋅12, 2⋅88) 0⋅510
ypT2 2⋅38 (1⋅24, 4⋅57) 0⋅009 0⋅49 (0⋅10, 2⋅38) 0⋅378
ypT3 5⋅00 (2⋅67, 9⋅34) <0⋅001 0⋅67 (0⋅14, 3⋅25) 0⋅623
ypT4 8⋅55 (4⋅35, 16⋅79) <0⋅001 0⋅94 (0⋅18, 4⋅80) 0⋅937
ypN category
ypN0 1⋅00 (reference) 1⋅00 (reference)
ypN1 2⋅78 (2⋅26, 3⋅43) <0⋅001 1⋅86 (1⋅04, 3⋅34) 0⋅038
ypN2 3⋅85 (3⋅04, 4⋅86) <0⋅001 2⋅50 (1⋅38, 4⋅51) 0⋅002
ypN3 7⋅72 (6⋅08, 9⋅81) <0⋅001 4⋅30 (2⋅36, 7⋅84) <0⋅001
ypM category
ypM0 1⋅00 (reference) 1⋅00 (reference)
ypM1 3⋅05 (2⋅10, 4⋅43) <0⋅001 2⋅51 (1⋅49, 4⋅25) 0⋅001
Vascular/lymphatic invasion
No 1⋅00 (reference) 1⋅00 (reference)
Yes 2⋅88 (2⋅33, 3⋅56) <0⋅001 1⋅61 (1⋅23, 2⋅10) < 0⋅001
Resection margin
R0 1⋅00 (reference) 1⋅00 (reference)
R1 2⋅23 (1⋅98, 2⋅67) <0⋅001 1⋅26 (0⋅97, 1⋅63) 0⋅086
Differentiation
G1 1⋅00 (reference) 1⋅00 (reference)
G2 1⋅71 (1⋅03, 2⋅85) 0⋅038 0⋅96 (0⋅52, 1⋅78) 0⋅888
G3 2⋅76 (1⋅68, 4⋅52) <0⋅001 1⋅08 (0⋅58, 1⋅99) 0⋅814
G4 2⋅71 (1⋅55, 4⋅76) <0⋅001 0⋅89 (0⋅43, 1⋅81) 0⋅742
Values in parentheses are 95 per cent confidence intervals. TRG, Tumour Regression Grade.
Evaluation of combined local tumour response
and lymph node downstaging
Some 85 (59⋅9 per cent) of the 142 patients with a
local response to NAC (TRG 1–2) also had regional
lymph nodes downstaged, compared with only 158 (21⋅3
per cent) of 743 non-responders (TRG 3–5) (P< 0⋅001)
(Fig. 4).
Lymph node downstaging in local non-responders (TRG
3–5) was associated with significantly improved OS (lymph
nodes downstaged: median OS not reached, mean OS 7⋅24
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Fig. 4 Effect of lymph node (LN) downstaging on survival. a Percentage of patients with LN downstaging grouped by Tumour
Regression Grade (TRG). b Kaplan–Meier curves for patients with local tumour response (TRG 1–2) compared with non-responders
(TRG 3–5) divided into those with evidence of LN downstaging or no downstaging. P< 0⋅001 (log rank test)
(95 per cent c.i. 6⋅50 to 7⋅99) years; lymph nodes not
downstaged: median OS 1⋅92 (1⋅68 to 2⋅16) years, mean
OS 3⋅29 (2⋅92 to 3⋅66) years; P< 0⋅001).
Discussion
In this multicentre study, a clinically meaningful local
response to NAC for adenocarcinomas of the oesoph-
agus and OGJ was restricted to the small minority of
patients (14⋅8 per cent) with TRG 1–2. Among apparent
local non-responders, there was a subset of patients who
appeared to derive additional benefit from NAC by lymph
node downstaging and their survival mirrored that of local
responders.
The difficulties faced by clinicians in routine practice
regarding what constitutes a meaningful response to NAC,
and how this information should be used to tailor subse-
quent treatment, has been caused primarily by the cohort
sizes of previous studies. For example, the Mandard sys-
tem was developed in 1994 in a cohort of 93 French
patients (84 per cent with squamous cell cancer) treated
with cisplatin and radiotherapy, and TRG 1–3 was found
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to correlate with improved disease-free survival23. In a
subsequent study performed in the UK and Ireland30,
TRG had no correlation with survival in 43 patients with
adenocarcinoma. More recent work from single institu-
tions has demonstrated the validity of the TRG system
in patients with oesophageal cancer treated with NAC,
but cohort sizes remain small (Fareed et al.19: 103 patients,
TRG 1–3 associated with a disease-specific survival advan-
tage; Noble et al.24: 136 patients, TRG 1–2 associated
with a disease-free survival advantage). Larger series have
focused on the role of NAC and tumour stage rather than
TRG31, or have included mainly gastric cancers25. In the
context of neoadjuvant chemoradiotherapy a three-point
scale for TRG, using TRG 1 compared with TRG 2–3
and TRG 4–5, was found to provide the best discriminant
fit of all response measurement modalities in a cohort of
393 patients from a single centre in Ireland32. The data
presented here do not support this classification, and sug-
gest that there may be differences in the histomorpho-
logical assessment of response between chemotherapy and
chemoradiation.
The strengths of the present study are its cohort size,
length of follow-up and multicentre nature. It shows that
TRG is a robust measure of local response to NAC in
routine clinical practice, with excellent correlation between
local centre scoring and central validation. The inclusion
of the two UK centres (Nottingham19 and Southampton24)
that previously published discordant results regarding the
level of TRG associated with a response adds weight to
the finding that only TRG 1–2 represents a group of
true local responders. This is supported by the use of
OS as the outcome measure here, and by the similarity
between responder and non-responder groups in terms of
pretreatment characteristics.
In contrast to the results of a recent subgroup analysis
of the Medical Research Council (MRC) Adjuvant Gastric
Infusional Chemotherapy (MAGIC) Trial25, where lymph
node status was the only independent predictor of survival
in patients treated with chemotherapy, in the present study
non-response to NAC (TRG 3–5) was independently asso-
ciated with poor overall survival. This probably reflects the
relative sizes of the study cohorts (1293 in the present study
versus 330 in MAGIC25). In the present study, no attempt
was made to assess the value of postoperative chemotherapy
in either responders or non-responders. In a recent study
of 333 patients from a single UK centre33, only respon-
ders to NAC were observed to derive a survival advan-
tage from the adjuvant part of the MAGIC regimen, and
there was evidence of potential harm for non-responders
in terms of chemotherapy morbidity. The question of
who should receive adjuvant treatment and what form this
should take needs to be addressed urgently in prospective
studies, so that futile overtreatment with chemotherapy
can be avoided and therapies can be targeted more effec-
tively where appropriate. TRG and lymph node downstag-
ing could be used to stratify patients while the validation of
recently discovered mutational endotypes takes place28.
This study was not designed to investigate differences in
outcome between different chemotherapy regimens.
However, the data clearly show the superiority of
platinum-based triplet chemotherapy, including epiru-
bicin, over cisplatin and 5-FU for local tumour response,
but this did not translate into better survival. These find-
ings are in keeping with the results of the MRC OEO5
trial34, in which two cycles of neoadjuvant cisplatin and
5-FU was shown to be equivalent to four cycles of ECX for
overall survival, with higher chemotherapy-related toxicity
in the ECX group34. Widely regarded as a negative trial,
OEO5 is important because it identifies the requirement
for robust markers of patient and tumour stratification to
guide precision treatment.
There are clear drawbacks when performing a large
multicentre cohort study over a relatively long period. This
was not a randomized trial and there are missing data, so
bias cannot be excluded, but the sample size helps to negate
this deficiency. Staging modalities, chemotherapy and to a
lesser extent surgery will have changed over the study inter-
val. It is possible that a number of patients who received
treatment at the beginning of the study may have been
excluded from treatment had they been staged using mod-
ern imaging, leading to worsened OS. It could be presumed
that these patients would be in the non-responder group, as
there is some evidence to support the association between
local tumour response and systemic relapse, but tumour
stage after NAC seems to be more important than ini-
tial stage at presentation in terms of assessing prognosis31.
These drawbacks may also explain the relatively low over-
all R0 resection rate (66⋅6 per cent), but it is important to
note that the circumferential margin was involved in the
majority of R1 resections and the more stringent Royal
College of Pathologists’ definition of margin involvement
was used. No attempt has been made to assess the theor-
etical benefit of using NAC (rather than neoadjuvant
chemoradiotherapy) to treat distant micrometastatic dis-
ease in these patients. Ongoing randomized studies will
hopefully answer this important question.
The finding that a small group (approximately 20 per
cent) of patients whose primary tumours apparently do not
respond to NAC have downstaging of local nodes and asso-
ciated good long-term survival, similar to that of primary
tumour responders, is important both for discussions of
prognosis with individual patients and for the design of
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the next generation of trials of tailored adjuvant treatment.
The use of cN category to assess involvement of nodes
before operation compared with postoperative ypN status
to determine downstaging is open to criticism. In support
of this strategy, it has been shown previously that patients
with ypN0 disease have worse OS than those with pN0 dis-
ease, suggesting true nodal involvement24, and downstag-
ing has been demonstrated accurately in other cohorts31.
This also reflects current clinical practice in the UK and
elsewhere. However, an alternative interpretation of these
data is that they are indicative of clinical overstaging rather
than downstaging. A future analysis should consider the
pathological assessment of nodal downstaging to look for
evidence of fibrosis/previous tumour in the nodes, and the
relationship between this and prognosis. Large-scale col-
laborations such as the OCCAMS consortium are ideally
placed to do this.
As the research community begins to consider the move
from binary ‘one size fits all’ treatment and trial designs
to more personalized strategies, robust markers of treat-
ment response will be required. The present findings con-
firm TRG as such a marker and clearly define groups of
patients who benefit from NAC. In addition, giving clar-
ity to the assessment of response offers the opportunity to
determine biomarkers that may predict response to exist-
ing and novel neoadjuvant treatments, whether they are
patient-, tumour- or treatment-related.
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